Is elacestrant a targeted drug?

Elacestrant is a novel targeted drug indicated for the treatment of advanced or metastatic breast cancer in postmenopausal women or adult men, specifically those with estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) patients who express ESR1 mutations. As a selective estrogen receptor degrader (SERD), it reduces the growth and expansion of breast cancer cells by inhibiting the function of the estrogen receptor (ER) and is therefore classified as a targeted drug.

Elagrastrant works through a different mechanism than traditional endocrine therapies such as tamoxifen and anastrozole. Although these traditional drugs are also used to treat ER+ breast cancer, they mainly inhibit tumor growth by blocking the binding of estrogen to receptors, while elastran binds to estrogen receptors and promotes receptor degradation, fundamentally reducing the dependence of cancer cells on estrogen, thereby effectively inhibiting tumor progression.

In addition, elastran is specifically indicated for the treatment of patients whose disease has progressed after at least one endocrine therapy, particularly those withESR1 mutations. ESR1 mutations are an important factor in the development of drug resistance in breast cancer, making elastran a new treatment option for these specific patient groups. Traditional endocrine therapy may be ineffective in some breast cancer patients, especially those with ESR1 mutations. Elastran can effectively overcome this resistance, making it an important treatment option for patients with advanced breast cancer.

In the field of targeted therapy, the emergence of elastran has brought new hope for the treatment of breast cancer. It has strong targeting ability and can precisely act on estrogen receptors, especially in patients who are resistant to traditional endocrine therapy, showing obvious therapeutic effects.

References:https://www.drugs.com/mtm/elacestrant.html